Biochem Pharma (BCHE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (763)	7/22/2000 10:09:26 PM
From: Jim Oravetz	Read Replies (1) of 783

European CPMP Gives Positive Opinion on Trizivir, a New Triple Combination Therapy for HIV July 18th Laval, Quebec, Canada — BioChem Pharma Inc. (NASDAQ: BCHE; TSE: BCH) announced today that the European Union’s Committee for Proprietary Medicinal Products (CPMP) has recommended the approval of Trizivir, Glaxo Wellcome’s new triple combination tablet developed for the treatment of HIV-infected adults, in the 15 member states of the European Union. The CPMP’s opinion will now be considered by the European Commission for a final decision. Trizivir, which includes BioChem’s discovery 3TC/Epivir, is the first medicine to combine three anti-HIV therapies in one tablet. snip<> biochempharma.com jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next